What is Saama?
Founded in 1997, Saama Technologies has evolved into a cornerstone of modern clinical research. The company specializes in an AI-driven clinical data analytics platform that integrates, curates, and animates diverse data streams—ranging from structured clinical trial results to unstructured real-world evidence. By bridging the gap between raw data and therapeutic decision-making, Saama enables pharmaceutical companies to streamline drug development cycles and improve patient outcomes across all therapeutic areas. Its market position is defined by its ability to handle the high-velocity data requirements of modern clinical trials, making it an essential utility for organizations navigating the complexities of global health innovation.
How much funding has Saama raised?
Saama has raised a total of $507M across 4 funding rounds:
Series A
$35M
Private Equity
$40M
Debt
$2M
Other Financing Round
$430M
Series A (2015): $35M with participation from Carrick Capital Partners
Private Equity (2019): $40M led by Perceptive Advisors
Debt (2020): $2M supported by PPP
Other Financing Round (2021): $430M featuring Amgen Business Development, Merck Global Health Innovation Fund, and Northpond Ventures
Key Investors in Saama
Amgen Business Development
Amgen Oncology is dedicated to transforming cancer treatment through innovative therapies and a commitment to patient care, focusing on delivering high-quality medicines to enhance treatment options.
Merck Global Health Innovation Fund
Merck Global Health Innovation Fund is a growth investor that partners with innovative digital health and data science companies to facilitate and optimize biopharmaceutical operations.
Northpond Ventures
Northpond Ventures is a prominent investment firm focused on supporting high-growth companies at the intersection of science and technology.
What's next for Saama?
Looking ahead, Saama is poised to leverage its recent capital injection to deepen its integration with major biopharmaceutical workflows. The strategic focus will likely center on enhancing the scalability of its AI models to accommodate the increasing volume of real-world data in oncology and other complex therapeutic fields. As the company matures, it is expected to prioritize the expansion of its data curation capabilities, ensuring that its platform remains the gold standard for clinical intelligence. By fostering deeper partnerships with industry leaders and continuing its commitment to data-driven precision, Saama is set to play a transformative role in the future of digital health and biopharmaceutical operations.
See full Saama company page
